Telomir Pharmaceuticals Publishes Positive Preclinical Data for Telomir-Zn in Wilson's Disease
TELO sits 22% above its 52-week low of $1.05.
Summary
Telomir Pharmaceuticals announced the peer-reviewed publication of positive preclinical data for Telomir-Zn in a Wilson's disease model, demonstrating improved survival and reduced oxidative stress, which also supports its lead cancer program.
Key Events · Product Development and Regulatory · TELO
-
Peer-Reviewed Publication
Telomir Pharmaceuticals announced the publication of a peer-reviewed preclinical study on Telomir-Zn (Telomir-1) in the journal *Advances in Redox Research*.
-
Positive Preclinical Results
The study reported dose-dependent survival improvement, reductions in oxidative stress, decreased hepatic copper accumulation, improved liver injury biomarkers, and enhanced locomotor performance in a zebrafish model of Wilson's disease.
-
Mechanistic Validation for Lead Program
The findings support the mechanistic relevance of Telomir-Zn's approach for its lead program in Triple-Negative Breast Cancer, for which the company received FDA IND clearance in April 2026.
Analysis · TELO · Life Sciences
This 8-K announces the peer-reviewed publication of preclinical data for Telomir-Zn (Telomir-1) in a Wilson's disease model. The study demonstrated dose-dependent survival improvement, reduced oxidative stress, and improved liver function, among other benefits. This scientific validation supports the drug's mechanism of action, which is also relevant to the company's lead program in Triple-Negative Breast Cancer, for which an IND was recently cleared. The positive preclinical results provide scientific backing for Telomir's pipeline as it navigates recent financial challenges and significant dilution.
At the time of this filing, TELO was trading at $1.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $83.9M. The 52-week trading range was $1.05 to $3.10. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.